Login Register Cart 0
Generic placeholder image

Reviews on Recent Clinical Trials

Editor-in-Chief

ISSN (Print): 1574-8871
ISSN (Online): 1876-1038

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Clinical Trial

Evaluation of Urolithin A Efficacy in Heart Failure Patients with Reduced Ejection Fraction: A Randomized, Double-blind, Crossover, Placebo-controlled Clinical Trial

Author(s): Tannaz Jamialahmadi, Maede Hasanpour, Farveh Vakilian, Peter E. Penson, Milad Iranshahy* and Amirhossein Sahebkar*

Volume 19, Issue 3, 2024

Published on: 20 February, 2024

Page: [221 - 228] Pages: 8

DOI: 10.2174/0115748871279354240209101604

Price: $65

Abstract

Background: Mitochondrial dysfunction and impaired mitophagy are integral to myocyte loss and the progression of heart failure. Urolithin A (UA), a microbiota-produced metabolite of ellagitannins and ellagic acid, is a known stimulator of mitophagy and mitochondrial biogenesis that has shown cardioprotective effects in experimental models.

Methods: A randomized, double-blind, placebo-controlled 2×2 crossover trial was conducted on 10 patients with HF with reduced ejection fraction (HFrEF). The trial design involved two 4- week intervention periods of UA (500 mg BID) and placebo, separated by a 2-week washout phase. The patients underwent two-dimensional echocardiogram examination as well as blood sampling at the beginning and end of each period.

Results: All patients completed the study. The results failed to reveal any significant effect of UA supplementation on echocardiographic measures (LVEF, LVEDD, LVESV, and TAPSE). Plasma concentrations of pro-BNP, glucose, and CRP (p >0.05) were also not altered. Serum HDL-C levels were increased with UA compared with placebo (+6.46 ± 2.33 mg/dL, p =0.026), whereas other lipid indices (LDL-C, triglycerides, total cholesterol, and VLDL-C) remained unchanged (p >0.05).

Conclusion: The results of the present study do not support any positive effect of UA supplementation in improving echocardiographic and biochemical indices of HFrEF. Further studies with higher doses of UA and longer supplementation duration are encouraged to be conducted.

Keywords: Urolithin A, mitochondrial dysfunction, ellagic acid, cardioprotective, echocardiography, heart failure.

« Previous
Graphical Abstract

[1]
Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396(10258): 1204-22.
[http://dx.doi.org/10.1016/S0140-6736(20)30925-9] [PMID: 33069326]
[2]
Mensah GA, Roth GA, Fuster V. The global burden of cardiovascular diseases and risk factors. J Am Coll Cardiol 2019; 74(20): 2529-32.
[http://dx.doi.org/10.1016/j.jacc.2019.10.009] [PMID: 31727292]
[3]
The world health report 2002: reducing risks, promoting healthy life. World Health Organization 2002.
[4]
Mendis S, Puska P. Norrving Be, Organization WH Global atlas on cardiovascular disease prevention and control. World Health Organization 2011.
[5]
Abubakar I, Tillmann T, Banerjee A. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385(9963): 117-71.
[http://dx.doi.org/10.1016/S0140-6736(14)61682-2] [PMID: 25530442]
[6]
Kemp CD, Conte JV. The pathophysiology of heart failure. Cardiovasc Pathol 2012; 21(5): 365-71.
[http://dx.doi.org/10.1016/j.carpath.2011.11.007] [PMID: 22227365]
[7]
Tanai E, Frantz S. Pathophysiology of heart failure. Compr Physiol 2015; 6(1): 187-214.
[http://dx.doi.org/10.1002/cphy.c140055] [PMID: 26756631]
[8]
Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. Circulation 2007; 116(4): 434-48.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.107.702795] [PMID: 17646594]
[9]
Dassanayaka S, Jones SP. Recent developments in heart failure. Circ Res 2015; 117(7): e58-63.
[http://dx.doi.org/10.1161/CIRCRESAHA.115.305765] [PMID: 26358111]
[10]
Inamdar A, Inamdar A. Heart failure: Diagnosis, management and utilization. J Clin Med 2016; 5(7): 62.
[http://dx.doi.org/10.3390/jcm5070062] [PMID: 27367736]
[11]
McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371(11): 993-1004.
[http://dx.doi.org/10.1056/NEJMoa1409077] [PMID: 25176015]
[12]
Shah A, Gandhi D, Srivastava S, Shah KJ, Mansukhani R. Heart failure: A class review of pharmacotherapy. P&T 2017; 42(7): 464-72.
[PMID: 28674474]
[13]
Shires SE, Gustafsson ÅB. Mitophagy and heart failure. J Mol Med 2015; 93(3): 253-62.
[http://dx.doi.org/10.1007/s00109-015-1254-6] [PMID: 25609139]
[14]
Yang Y, Li T, Li Z, Liu N, Yan Y, Liu B. Role of mitophagy in cardiovascular disease. Aging Dis 2020; 11(2): 419-37.
[http://dx.doi.org/10.14336/AD.2019.0518] [PMID: 32257551]
[15]
Hasheminezhad SH, Boozari M, Iranshahi M, et al. A mechanistic insight into the biological activities of urolithins as gut microbial metabolites of ellagitannins. Phytother Res 2022; 36(1): 112-46.
[http://dx.doi.org/10.1002/ptr.7290] [PMID: 34542202]
[16]
Cerdá B, Llorach R, Cerón JJ, Espín JC, Tomás-Barberán FA. Evaluation of the bioavailability and metabolism in the rat of punicalagin, an antioxidant polyphenol from pomegranate juice. Eur J Nutr 2003; 42(1): 18-28.
[http://dx.doi.org/10.1007/s00394-003-0396-4] [PMID: 12594538]
[17]
Cerdá B, Espín JC, Parra S, Martínez P, Tomás-Barberán FA. The potent in vitro antioxidant ellagitannins from pomegranate juice are metabolised into bioavailable but poor antioxidant hydroxy-6H-dibenzopyran-6-one derivatives by the colonic microflora of healthy humans. Eur J Nutr 2004; 43(4): 205-20.
[http://dx.doi.org/10.1007/s00394-004-0461-7] [PMID: 15309440]
[18]
Heilman J, Andreux P, Tran N, Rinsch C, Blanco-Bose W. Safety assessment of Urolithin A, a metabolite produced by the human gut microbiota upon dietary intake of plant derived ellagitannins and ellagic acid. Food Chem Toxicol 2017; 108(Pt A): 289-97.
[http://dx.doi.org/10.1016/j.fct.2017.07.050] [PMID: 28757461]
[19]
Andreux PA, Blanco-Bose W, Ryu D, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat Metab 2019; 1(6): 595-603.
[http://dx.doi.org/10.1038/s42255-019-0073-4] [PMID: 32694802]
[20]
Wu X, Zhu X, Zhou Y. Urolithin a suppress cardiac fibrosis via autophagy pathway in the diabetic cardiomyopathy. Circulat Res 2019; 125(S1): A531.
[http://dx.doi.org/10.1161/res.125.suppl_1.531]
[21]
Savi M, Bocchi L, Mena P, et al. In vivo administration of urolithin A and B prevents the occurrence of cardiac dysfunction in streptozotocin-induced diabetic rats. Cardiovasc Diabetol 2017; 16(1): 80.
[http://dx.doi.org/10.1186/s12933-017-0561-3] [PMID: 28683791]
[22]
Ganjali S, Matbou Riahi M, Mahboobnia K, et al. An in vitro investigation of the effects of urolithins A and B on low-density lipoprotein uptake and its regulatory genes. Arch Med Sci 2023; 19(6): 1832-41.
[PMID: 38058736]
[23]
Tang L, Mo Y, Li Y, et al. Urolithin A alleviates myocardial ischemia/reperfusion injury via PI3K/Akt pathway. Biochem Biophys Res Commun 2017; 486(3): 774-80.
[http://dx.doi.org/10.1016/j.bbrc.2017.03.119] [PMID: 28343995]
[24]
Lim CY, In J. Considerations for crossover design in clinical study. Korean J Anesthesiol 2021; 74(4): 293-9.
[http://dx.doi.org/10.4097/kja.21165] [PMID: 34344139]
[25]
Penson PE, Banach M. Nutraceuticals for the control of dyslipidaemias in clinical practice. Nutrients 2021; 13(9): 2957.
[http://dx.doi.org/10.3390/nu13092957] [PMID: 34578834]
[26]
Banach M, Katsiki N, Latkovskis G, et al. Postmarketing nutrivigilance safety profile: A line of dietary food supplements containing red yeast rice for dyslipidemia. Arch Med Sci 2021; 17(4): 856-63.
[http://dx.doi.org/10.5114/aoms/133716] [PMID: 34336013]
[27]
Penson P, Long DL, Howard G, et al. Associations between cardiovascular disease, cancer, and very low high-density lipoprotein cholesterol in the REasons for Geographical and Racial Differences in Stroke (REGARDS) study. Cardiovasc Res 2019; 115(1): 204-12.
[http://dx.doi.org/10.1093/cvr/cvy198] [PMID: 30576432]
[28]
Penson PE, Mancini GBJ, Toth PP, et al. Introducing the ‘Drucebo’ effect in statin therapy: A systematic review of studies comparing reported rates of statin‐associated muscle symptoms, under blinded and open‐label conditions. J Cachexia Sarcopenia Muscle 2018; 9(6): 1023-33.
[http://dx.doi.org/10.1002/jcsm.12344] [PMID: 30311434]

Rights & Permissions Print Cite
Article Metrics
17
1
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy